ARWR vs. ALNY

Last updated Apr 1, 2026

Compare and contrast key facts about Arrowhead Pharmaceuticals, Inc. (ARWR) and Alnylam Pharmaceuticals, Inc. (ALNY).

Performance

ARWR vs. ALNY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arrowhead Pharmaceuticals, Inc. (ARWR) and Alnylam Pharmaceuticals, Inc. (ALNY). The values are adjusted to include any dividend payments, if applicable.

ARWR vs. ALNY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARWR Arrowhead Pharmaceuticals, Inc.	-5.56%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	410.71%	237.50%	137.42%
ALNY Alnylam Pharmaceuticals, Inc.	-16.79%	68.99%	22.94%	-19.46%	40.14%	30.48%	12.85%	57.96%	-42.61%	239.34%

Fundamentals

Market Cap ARWR : $8.82B ALNY : $45.09B
EPS ARWR : $1.46 ALNY : $2.33
PE Ratio ARWR : 42.93 ALNY : 141.77
PS Ratio ARWR : 7.96 ALNY : 11.98
PB Ratio ARWR : 15.52 ALNY : 57.14
Total Revenue (TTM) ARWR : $1.09B ALNY : $3.71B
Gross Profit (TTM) ARWR : $1.08B ALNY : $3.04B
EBITDA (TTM) ARWR : $360.26M ALNY : $472.68M

Returns By Period

In the year-to-date period, ARWR achieves a -5.56% return, which is significantly higher than ALNY's -16.79% return. Over the past 10 years, ARWR has outperformed ALNY with an annualized return of 29.03%, while ALNY has yielded a comparatively lower 17.71% annualized return.

ARWR

• 1D: 8.76%
• 1M: -0.90%
• YTD: -5.56%
• 6M: 81.79%
• 1Y: 392.15%
• 3Y*: 35.15%
• 5Y*: -1.34%
• 10Y*: 29.03%

ALNY

• 1D: 4.68%
• 1M: -0.62%
• YTD: -16.79%
• 6M: -27.44%
• 1Y: 22.54%
• 3Y*: 18.21%
• 5Y*: 18.47%
• 10Y*: 17.71%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARWR vs. ALNY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARWR

ARWR Risk / Return Rank: 99
ARWR Sharpe Ratio Rank: 99
ARWR Sortino Ratio Rank: 98
ARWR Omega Ratio Rank: 97
ARWR Calmar Ratio Rank: 99
ARWR Martin Ratio Rank: 99

ALNY

ALNY Risk / Return Rank: 58
ALNY Sharpe Ratio Rank: 62
ALNY Sortino Ratio Rank: 58
ALNY Omega Ratio Rank: 57
ALNY Calmar Ratio Rank: 57
ALNY Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARWR vs. ALNY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARWR	ALNY	Difference
Sharpe ratio Return per unit of total volatility	5.59	0.55	+5.05
Sortino ratio Return per unit of downside risk	4.63	1.05	+3.57
Omega ratio Gain probability vs. loss probability	1.60	1.14	+0.47
Calmar ratio Return relative to maximum drawdown	14.35	0.62	+13.73
Martin ratio Return relative to average drawdown	39.33	1.38	+37.95
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARWR vs. ALNY - Sharpe Ratio Comparison

The current ARWR Sharpe Ratio is 5.59, which is higher than the ALNY Sharpe Ratio of 0.55. The chart below compares the historical Sharpe Ratios of ARWR and ALNY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARWR	ALNY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	5.59	0.55	+5.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.02	0.38	-0.40
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.39	0.33	+0.07
Sharpe Ratio (All Time) Calculated using the full available price history	-0.01	0.34	-0.35

Correlation

The correlation between ARWR and ALNY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARWR vs. ALNY - Dividend Comparison

Neither ARWR nor ALNY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ARWR vs. ALNY - Drawdown Comparison

The maximum ARWR drawdown since its inception was -99.24%, which is greater than ALNY's maximum drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for ARWR and ALNY.

Drawdown Indicators

	ARWR	ALNY	Difference
Max Drawdown Largest peak-to-trough decline	-99.24%	-83.58%	-15.66%
Max Drawdown (1Y) Largest decline over 1 year	-24.64%	-37.57%	+12.93%
Max Drawdown (5Y) Largest decline over 5 years	-88.94%	-42.46%	-46.48%
Max Drawdown (10Y) Largest decline over 10 years	-88.96%	-59.95%	-29.01%
Current Drawdown Current decline from peak	-61.42%	-32.64%	-28.78%
Average Drawdown Average peak-to-trough decline	-81.40%	-30.53%	-50.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.99%	16.81%	-7.82%

Volatility

ARWR vs. ALNY - Volatility Comparison

Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 16.63% compared to Alnylam Pharmaceuticals, Inc. (ALNY) at 10.49%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than ALNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARWR	ALNY	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.63%	10.49%	+6.14%
Volatility (6M) Calculated over the trailing 6-month period	46.06%	25.91%	+20.15%
Volatility (1Y) Calculated over the trailing 1-year period	71.17%	41.46%	+29.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.68%	48.70%	+15.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.13%	54.25%	+19.88%

Financials

ARWR vs. ALNY - Profitability Comparison

The chart below illustrates the profitability comparison between Arrowhead Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ARWR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a gross profit of 264.03M and revenue of 264.03M. Therefore, the gross margin over that period was 100.0%.

ALNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 834.02M and revenue of 1.10B. Therefore, the gross margin over that period was 76.0%.

ARWR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported an operating income of 40.81M and revenue of 264.03M, resulting in an operating margin of 15.5%.

ALNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 131.72M and revenue of 1.10B, resulting in an operating margin of 12.0%.

ARWR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a net income of 30.81M and revenue of 264.03M, resulting in a net margin of 11.7%.

ALNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 186.42M and revenue of 1.10B, resulting in a net margin of 17.0%.